Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Trial of the Safety and Tolerability of Tumor-Associated Lymph Node T-Cell Injection (TAL-T) in Subjects With Advanced Malignant Solid Tumors

NCT06716619 is registered in ClinicalTrials.gov with Guangzhou FineImmune Biotechnology Co., LTD. as lead sponsor.

NCT NCT06716619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06716619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Trial of the Safety and Tolerability of Tumor-Associated Lymph Node T-Cell Injection (TAL-T) in Subjects With Advanced Malignant Solid Tumors
Lead sponsor
Guangzhou FineImmune Biotechnology Co., LTD.
Phase
Phase 1
Overall status
Recruiting
Start date
February 13, 2025
Completion date
December 19, 2027
Enrollment
32 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, immunotherapy, serplulimab injection, tumor associated lymph node t cell